Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 9:13 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2545–2568 of 14,150 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Safety Control Clear all

Conditions: Heart Failure
Interventions: Placebo, Low Dose PF-07328948, Medium Dose PF-07328948, High Dose PF-07328948; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 620 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 30
States / cities: Beverly Hills, California • Lake Forest, California • Santa Maria, California + 18 more

Conditions: Meniere's Disease
Interventions: SPI-1005; Drug
Lead sponsor: Sound Pharmaceuticals, Incorporated; Industry
Eligibility: 19 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 5
States / cities: Los Angeles, California • New York, New York • Charleston, South Carolina + 1 more

Conditions: Venous Leg Ulcer
Interventions: EscharEx (5% EX-02 formulation), Gel Vehicle, Non-surgical standard of care (NSSOC); Drug
Lead sponsor: MediWound Ltd; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 21
States / cities: Carlsbad, California • Fresno, California • Los Angeles, California + 17 more

Conditions: Age-related Macular Degeneration (AMD)
Interventions: LMG324, Ranibizumab 0.5 mg, Sham; Biological
Lead sponsor: Alcon Research; Industry
Eligibility: 50 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Healthy Volunteers, Primary Sclerosing Cholangitis
Interventions: TAK-781, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 68 Years
Enrollment: 134 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Tuberculosis
Interventions: TBA-354, Placebo; Drug · Other
Lead sponsor: Global Alliance for TB Drug Development; Other
Eligibility: 19 Years to 50 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Narcolepsy Type 1
Interventions: Oveporexton, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 16 Years to 70 Years
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 15
States / cities: Phoenix, Arizona • Redwood City, California • Santa Ana, California + 12 more

Conditions: Oral Mucositis
Interventions: AG013, Placebo; Biological · Other
Lead sponsor: Oragenics, Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 27
States / cities: Farmington, Connecticut • Newark, Delaware • Orlando, Florida + 24 more

Conditions: Suicide Attempt, Suicide Ideation
Interventions: Psychoeducation about Suicide Crisis Resources (Control Intervention), Experimental: Self-Guided Electronic Safety Plan Intervention; Behavioral
Lead sponsor: University of Denver; Other
Eligibility: 13 Years to 17 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Acute Bacterial Skin and Skin Structure Infections
Interventions: Tedizolid phosphate, Comparator; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 1 Day to 11 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 8
States / cities: San Diego, California • Chicago, Illinois • Detroit, Michigan + 5 more

Conditions: Idiopathic Parkinson's Disease
Interventions: apomorphine infusion; Drug
Lead sponsor: MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals; Industry
Eligibility: 30 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2025
U.S. locations: 18
States / cities: Phoenix, Arizona • Loma Linda, California • Los Angeles, California + 13 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Olodaterol (BI 1744), Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 644 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 28
States / cities: Mobile, Alabama • Wheat Ridge, Colorado • Waterbury, Connecticut + 23 more

Conditions: Major Depressive Disorder
Interventions: AZD7268, Escitalopram, Placebo capsules, Placebo tablets; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 17
States / cities: Birmingham, Alabama • Garden Grove, California • San Diego, California + 14 more

Conditions: Seasonal Allergic Rhinitis
Interventions: Placebo comparator, Grass MATA MPL; Biological
Lead sponsor: Allergy Therapeutics; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 4
States / cities: Edison, New Jersey • Ocean City, New Jersey • Springfield, New Jersey + 1 more

Conditions: Clostridium Difficile
Interventions: Misoprostol 100Mcg Tab, Placebo; Drug · Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 3
States / cities: St Louis, Missouri • Chapel Hill, North Carolina • Nashville, Tennessee

Conditions: Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Retinopathy of Prematurity, Bronchopulmonary Dysplasia (BPD)
Interventions: Inositol lower volume, Inositol mid-level volume, Inositol high volume, Placebo low volume; Drug
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: 12 Hours to 72 Hours
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 17
States / cities: Birmingham, Alabama • Palo Alto, California • New Haven, Connecticut + 13 more

Conditions: Alzheimer Disease
Interventions: Placebo, BI 409306, Donepezil; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 55 Years and older
Enrollment: 329 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 10
States / cities: Sherman Oaks, California • Orlando, Florida • West Palm Beach, Florida + 7 more

Conditions: Head and Neck Squamous Cell Carcinoma, Oral Mucositis
Interventions: MIT-001 plus CCRT; Drug
Lead sponsor: MitoImmune Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 6
States / cities: Gilbert, Arizona • Los Angeles, California • Wichita, Kansas + 3 more

Conditions: Crohn Disease
Interventions: JNJ-64304500, Placebo, Ustekinumab; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 388 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 37
States / cities: Lone Tree, Colorado • Coral Gables, Florida • Kissimmee, Florida + 34 more

Conditions: Post Operative Pain
Interventions: Sufentanil NanoTab, Placebo NanoTab; Drug
Lead sponsor: Talphera, Inc; Industry
Eligibility: 45 Years to 80 Years
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Lip Augmentation
Interventions: PN40082; Device
Lead sponsor: Prollenium Medical Technologies Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 5
States / cities: Encinitas, California • Miami, Florida • Omaha, Nebraska + 2 more

Conditions: Metastatic Colorectal Cancer, Metastatic Colon Cancer
Interventions: Fruquintinib, Placebo; Drug
Lead sponsor: Hutchison Medipharma Limited; Industry
Eligibility: 18 Years and older
Enrollment: 691 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 45
States / cities: Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 39 more

Conditions: Idiopathic Pulmonary Fibrosis (IPF)
Interventions: Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs), matched placebo; Biological
Lead sponsor: Joshua M Hare; Other
Eligibility: 40 Years to 90 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Wound Care, Venous Ulcer Care, Wound Cleansing, Chronic Wound Care
Interventions: Prontosan wound irrigation solution; Device
Lead sponsor: Calvary Hospital, Bronx, NY; Other
Eligibility: 18 Years to 95 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: The Bronx, New York

Search by objective public record fields.

A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)

Study to Evaluate SPI-1005 in Adults With Meniere's Disease

A Study to Evaluate the Safety and the Efficacy of EscharEx (EX-02 Formulation) in Debridement of Venous Leg Ulcers

Safety Tolerability and Efficacy of Intravitreal LMG324 in the Treatment of Neovascular Age-Related Macular Degeneration

A Study of TAK-781 in Healthy Volunteers and in Participants With Non-Cirrhotic Primary Sclerosing Cholangitis (PSC)

A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects

A Study of TAK-861 for the Treatment of Narcolepsy Type 1

Efficacy, Safety and Tolerability of AG013 in Oral Mucositis Compared to Placebo When Administered Three Times Per Day

Electronic, Self-Guided Safety Plan in Adolescents: Project SAFER

A Study of Safety and Efficacy of MK-1986 (Tedizolid Phosphate) and Comparator in Participants From Birth to Less Than 12 Years of Age With Acute Bacterial Skin and Skin Structure Infections (MK-1986-018)

Infusion of Apomorphine: Long-term Safety Study

12 / 48 wk Pivotal PFT vs PBO in COPD II

AZD7268 Safety and Tolerability Study

A Study of Tolerability and Safety of a New Cumulative Dose of Grass MATA MPL

PROCLAIM -- Misoprostol in the Prevention of Recurrent CDI Prevent Recurrence of Clostridium Difficile Infection With Misoprostol

Multi-dose Pharmacokinetics and Dose Ranging of Inositol in Premature Infants (INS-2)

BI 409306 in Patients With Cognitive Impairment Due to Alzheimer's Disease.

MIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients

Safety and Efficacy Study of JNJ-64304500 in Participants With Moderately to Severely Active Crohn's Disease

A Multicenter, Randomized, Placebo-Controlled Phase 2 Study to Evaluate the Clinical Efficacy, Safety, and Tolerability of ARX-F01 Sublingual Sufentanil in Patients Undergoing Elective Unilateral Total Knee Replacement

A Multicenter, Double-blind, Randomized, Controlled, Roll-over Retreatment Study of the Safety and Pain Associated With Injections of PN40082, RV001 With Topical Anesthetic or RV001 for Lip Augmentation

A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer

Allogeneic Human Cells (hMSC)in Patients With Idiopathic Pulmonary Fibrosis Via Intravenous Delivery (AETHER)

Effect of Prontosan Wound Irrigation Solution on Venous Ulcers